Skip to main content

Alnylam Pharmaceuticals(ALNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low200.65
Day High204.95
Open:201.33
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Latest News

Alnylam Announces New Management Appointments
Business Wire - Wed Sep 21, 3:00PM CDT
Business Wire
Wed Sep 21, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of two new members to the management team – Piyush Sharma as Chief Ethics & Compliance Officer (CECO), and Evan Lippman in...
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
Business Wire - Tue Sep 20, 6:00AM CDT
Business Wire
Tue Sep 20, 6:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing authorization for AMVUTTRA ® (vutrisiran), an RNAi therapeutic for the treatment of...
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
Business Wire - Mon Sep 19, 7:00AM CDT
Business Wire
Mon Sep 19, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9 th annual series of “RNAi Roundtable” webinars over the coming weeks. The series will offer presentations from...

Latest Articles

U.S. stocks with profit estimates in freefall
Roche backs RNAi research with $1-billion Alnylam deal
TSX slides lower
Inex shareholders OK spinout
Inex Pharma turns a profit
'New way of looking at cancer' sheds light on rogue cells